Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis. Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.
- Mechanism
- Curator reviewed
The exact mechanism by which teriflunomide acts in MS is not known. What is known is that teriflunomide prevents pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, and this may be involved in its immunomodulatory effect in MS.
- Primary indication
- Used in the treatment of relapsing forms of multiple sclerosis (MS).Curator reviewed · 1 structured indication
- Formula / weight
- C12H9F3N2O2 · 270.2073 g/mol (avg)
- First approval
- Canada, 2022 · United States, 2013 · European Union, 2016
- Code names
- A 77-1726 · HMR-1726
- Brand names
Resolves to
UTNUDOFZCWSZMS-YFHOEESVSA-NSMILESC\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)FWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Teriflunomide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account